Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF)

Clinica Chimica Acta

Volumn 412, Issue 23-24, 2011, Pages 2211-2215

  Kono, Masato ^a   Nakamura, Yutaro ^a   Suda, Takafumi ^a   Kato, Masato ^a   Kaida, Yusuke ^a   Hashimoto, Dai ^a   Inui, Naoki ^a   Hamada, Etsuko ^a   Miyazaki, Osamu ^b   Kurashita, Syunsuke ^b   Fukamachi, Isamu ^b   Endo, Koki ^c   Ng, Poh Sing ^c   Takehara, Kazuhiko ^d   Nakamura, Hirotoshi ^a   Maekawa, Masato ^a   Chida, Kingo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SEKISUI CHEMICAL CO LTD   (Japan)

^c Nosan Corporation   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

Author keywords

Biomarker; CCN2; Connective tissue growth factor (CTGF); Enzyme linked immunosorbent assay (ELISA); Idiopathic interstitial pneumonias (IIPs); Idiopathic pulmonary fibrosis (IPF)

Indexed keywords

BIOLOGICAL MARKER; CONNECTIVE TISSUE GROWTH FACTOR; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL PNEUMONIA; MALE; MEDICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

AGED; BIOLOGICAL MARKERS; CONNECTIVE TISSUE GROWTH FACTOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY FIBROSIS;

EID: 80053627987     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.08.008     Document Type: Article

References (38)

1. Katzenstein A.L., Myers J.L. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998, 157:1301-1315.
2. American Thoracic Society Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161:646-664.
3. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002, 165:277-304.
4. Nicholson A.G., Colby T.V., du Bois R.M., et al. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 2000, 162:2213-2217.
5. Flaherty K.R., Toews G.B., Travis W.D., et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002, 19:275-283.
6. Ohnishi H., Yokoyama A., Kondo K., et al. Comparative study of KL-6, Surfactant protein-A, Surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 2002, 165:378-381.
7. Yokoyama A., Kondo K., Nakajima M., et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006, 11:164-168.
8. Takahashi H., Fujishima T., Koba H., et al. Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med 2000, 162:1109-1114.
9. Greene K.E., King T.E., Kuroki Y., et al. Serum surfactant-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002, 19:439-446.
10. Bradham D.M., Igarashi A., Potter R.L., et al. Connective tissue growth factor: a cystein-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 1991, 114:1285-1294.
11. Proposal for a unified CCN nomenclature. Mol Pathol 2001, 54:108. [No authors listed].
12. Brigstock D.R., Goldschmeding R., Katsube K.I., et al. Proposal for a unified CCN nomenclature. Mol Pathol 2003, 56:127-128.
13. Bork P. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 1993, 327:125-130.
14. Brigstock D.R. The connective tissue growth factor/cystein-rich 61/nephroblastoma overexpressed (CCN) family. Endocr Rev 1999, 20:189-206.
15. Moussad E.E., Brigstock D.R. Connective tissue growth factor: what's in a name?. Mol Genet Metab 2000, 71:276-292.
16. Perbal B. CCN proteins: multifunctional signaling regulators. Lancet 2004, 363:62-64.
17. Blom I.E., Goldschmeding R., Leask A. Gene regulation of connective tissue growth factor: new target for antifibrotic therapy?. Matrix Biol 2002, 21:473-482.
18. Leask A., Abraham D.J. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 2006, 119:4803-4810.
19. Sato S., Nagaoka T., Hasegawa M., et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol 2000, 27:149-154.
20. Dziadzio M., Usinger W., Leask A., et al. N-terminal connective tissue growth factor is a marker of the fibrotic phenotype in scleroderma. Q J Med 2005, 98:485-492.
21. Leask A., Parapuram S.K., Shi-wen X., Abraham D.J. Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease?. J Cell Commun Signal 2009, 3:89-94.
22. Cicha I., Garlichs C.D., Daniel W.G., et al. Activated human platelets release connective tissue growth factor. Thromb Haemost 2004, 91:755-760.
23. Kubota S., Kawata K., Yanagita T., et al. Abundant retention and release of connective tissue growth factor (CTGF/CCN2) by platelets. J Biochem 2004, 136:279-282.
24. Miyazaki O., Kurashita S., Fukamachi I., et al. Subtraction method for determination of N-terminal connective tissue growth factor. Ann Clin Biochem 2010, 47:205-211.
25. Lasky J.A., Ortiz L.A., Tonthat B., et al. Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am J Physiol 1998, 275:L365-L371.
26. Allen J.T., Knight R.A., Bloor C.A., et al. Enhanced insulin-like growth factor binding protein-related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Cell Mol Biol 1999, 21:693-700.
27. Pan L.H., Yamauchi K., Uzuki M., et al. Type II alveolar epithelial cells and interstitial fibroblast express connective tissue growth factor in IPF. Eur Respir J 2001, 17:1220-1227.
28. Abreu J.G., Ketpura N.I., Reversade B., et al. Connective tissue growth factor (CTGF), modulates cell signaling by BMP and TGF-β. Nat Cell Biol 2002, 4:599-604.
29. King T.E., Tooze J.A., Schwarz M.I., et al. Predicting survival in idiopathic pulmonary fibrosis. Scoring system and survival model. Am J Respir Crit Care Med 2001, 164:1171-1181.
30. Lynch D.A., Goldwin J.D., Safrin S., et al. High-resolution computed tomography in idiopathic pulmonary fibrosis. Diagnosis and prognosis. Am J Respir Crit Care Med 2005, 172:488-493.
31. Sumikawa H., Johkoh T., Colby T.V., et al. Computed tomography findings in pathological usual interstitial pneumonia. Relationship to survival. Am J Respir Crit Care Med 2008, 177:433-439.
32. Latsi P.I., du Bois R.M., Nicholson A.G., et al. Fibrotic idiopathic interstitial pneumonia. The prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003, 168:531-537.
33. Collard H.R., King T.E., Bartelson B.B., et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003, 168:538-542.
34. Flaherty K.R., Mumford J.A., Murray S., et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003, 168:543-548.
35. Jegal Y., Kim D.S., Shim T.S., et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005, 171:639-644.
36. Shi-Wen X., Renzoni E.A., Kennedy L., et al. Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol 2007, 26:625-632.
37. Chen Y., Shi-wen X., Eastwood M., et al. Contribution of activin receptor-like kinase 5 (transforming growth factor beta receptor type I) signaling to the fibrotic phenotype of scleroderma fibroblasts. Arthritis Rheum 2006, 54:1309-1316.
38. Ponticos M., Holmes A.M., Shi-wen X., et al. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type-I collagen. Arthritis Rheum 2009, 60:2142-2155.